Table 1.
Patient baseline characteristics, final diagnosis, and management
| Characteristic | Women (n = 5288) | Men (n = 13 336) | P-value |
|---|---|---|---|
| Weight and BMI | |||
| Median body weight, kg (25th–75th percentile) | 71 (62–81) | 82 (73–92) | <0.0001 |
| Body weight <60 kg, % (n) | 16.7 (878) | 3.3 (434) | <0.0001 |
| Median BMI, kg/m2 (25th–75th percentile) | 27.5 (24.4–31.1) | 27.4 (24.8–30.2) | 0.1040 |
| Age ≥75 years | 23.7 (1251) | 12.2 (1627) | <0.0001 |
| Habitual smoker | 23.1 (1221) | 41.0 (5457) | <0.0001 |
| Hypertension | 76.8 (4058) | 61.0 (8125) | <0.0001 |
| Dyslipidaemia, including hypercholesterolaemia | 48.2 (2547) | 46.1 (6142) | 0.0090 |
| Angina pectoris | 48.6 (2568) | 43.4 (5790) | <0.0001 |
| Myocardial infarction | 17.8 (940) | 21.6 (2884) | <0.0001 |
| Congestive heart failure | 8.2 (431) | 4.6 (619) | <0.0001 |
| PCI | 10.9 (575) | 14.4 (1917) | <0.0001 |
| CABG | 4.2 (221) | 6.6 (885) | <0.0001 |
| TIA | 3.2 (169) | 2.5 (330) | 0.0059 |
| Non-haemorrhagic stroke | 4.6 (243) | 3.6 (479) | 0.0014 |
| PAD | 5.4 (287) | 6.4 (857) | 0.0106 |
| Chronic renal disease | 4.7 (247) | 4.0 (538) | 0.0508 |
| Baseline laboratory values, median (25th–75th percentile) | |||
| Glucose, mmol/L | 7.0 (5.8–9.2) | 6.8 (5.7–8.7) | <0.0001 |
| HbA1c, % | 6.1 (5.7–6.9) | 5.9 (5.6–6.5) | <0.0001 |
| EGFR, mL/min/1.73 m2 | 74 (59–89) | 86 (71–01) | <0.0001 |
| Final diagnosis, % (n) | |||
| STEMI | 30.6 (1613) | 40.7 (5413) | <0.0001 |
| NSTEMI | 43.0 (2266) | 42.8 (5689) | |
| Unstable angina | 22.8 (1202) | 14.3 (1910) | |
| Other | 3.6 (192) | 2.2 (297) | |
| Pre-randomization management strategy | |||
| Planned invasive, % (n) | 64.0 (3382) | 75.2 (10 026) | <0.0001 |
| Randomized to ticagrelor, % (n) | 50.2 (2655) | 50.1 (6678) | 0.8699 |
| Procedures during study | |||
| PCI before discharge | 51.0 (2698) | 65.0 (8665) | <0.0001 |
| PCI during study | 54.1 (2859) | 68.4 (9119) | <0.0001 |
| Coronary angiography before discharge | 74.4 (3935) | 84.3 (11 235) | <0.0001 |
| Coronary angiography during study | 79.2 (4187) | 88.4 (11 793) | <0.0001 |
| CABG before discharge | 4.0 (211) | 5.7 (759) | <0.0001 |
| CABG during study | 7.8 (411) | 11.2 (1488) | <0.0001 |
| Concomitant medication taken during study, % (n) | |||
| Aspirin | 95.8 (5062) | 96.5 (12 852) | 0.0317 |
| β-Blockers | 85.3 (4505) | 85.5 (11 390) | 0.6918 |
| ACE and/or angiotensin II inhibitors | 87.1 (4598) | 85.3 (11 363) | 0.0022 |
| Statins | 91.6 (4838) | 94.8 (12 622) | <0.0001 |
| Calcium channel inhibitors | 29.6 (1565) | 21.7 (2893) | <0.0001 |
| Diuretics | 49.4 (2607) | 38.3 (5100) | <0.0001 |
χ2 and Wilcoxon rank-sum tests were used for comparisons between sexes. No adjustments were made for multiple testing.
ACE, angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; EGFR, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin; NSTEMI, non-ST-elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischaemic attack